Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Earnings callYahoo Finance· February 28, 2026

St. Joe Q4 Earnings Call Highlights

View original at finance.yahoo.com
St. Joe Q4 Earnings Call Highlights St. Joe logo Key Points Strong Q4 and full-year performance: St. Joe posted a 24% revenue increase in Q4 and full-year revenue rose 27% to $513.2M, with net income up 56% to $115.6M and EPS of $2.00, supported by a shift to 56% recurring revenue…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q4 2025 revenue increased 24% and net income increased 58% versus prior-year period

    80% confidence
  • St. Joe repurchased 798,622 shares in 2025, compared with 70,985 in 2024, at an average price of $50.10 per share

    80% confidence
  • The company has been pleased with the early reception to its brokerage business, particularly the level of interest from agents seeking to join, while the business remains in its infancy

    80% confidence
  • Interest is a real cash expense and the company has been methodical in paying down project debt

    80% confidence
  • FSU Health campus first phase (80,000-square-foot medical office building) is essentially full, and the second phase—a teaching hospital and academic health center—is a potential catalyst for the corridor and broader region

    80% confidence
  • Not all debt is treated equally: long-term, HUD-insured apartment financing with very low fixed rates is not being targeted for paydown, while shorter-duration, higher-interest project debt may be reduced

    80% confidence
  • Management still views buybacks as a prudent use of capital even after a sharp rise in the share price

    80% confidence
  • 2025 marked the first time the company exceeded $500 million in revenue in 20 years, excluding a one-time large timberland sale in 2014

    80% confidence
  • Delta nonstop flight from New York early performance appears encouraging, with campaign translating into increased web traffic and early signs of higher occupancy and reservations from that region, though it is still early to predict long-term outcomes

    80% confidence
  • The company has received local and state approvals for 10 DSAPs (each at least 1,000 acres), and has only begun development in three of the 10

    80% confidence
  • Twenty years ago, the company had about 15% recurring revenue driven primarily by bulk asset sales; today it has 56% recurring revenue as a diversified real estate operating company

    80% confidence
  • 2025 was the first time St. Joe reached $2 per share EPS in 23 years

    80% confidence
  • The company plans to break ground on a new apartment complex focused on the vicinity of the FSU Health campus

    80% confidence
  • St. Joe transactions are not directly comparable to nearby transactions because the company includes back-end participation arrangements in homesite sales to builders, which vary by builder, community, and price point

    80% confidence
  • The company is in advanced discussions with one homebuilder new to the market for Pigeon Creek's more than 3,000 potential units and is cautiously optimistic about converting discussions into action relatively soon

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com